KIR2DL3

KIR2DL3 Overview

English Name	Killer cell immunoglobulin-like receptor 2DL3	Approved Drugs	0
Drugs in Clinical Trials	1	Target Synonym	P58.2 MHC Class-I Specific NK Receptor，MHC Class I NK Cell Receptor，CD158b2 Antigen，KIR-K7b，KIR-K7c，KIR2DS5，CD158b，KIR2DL，NKAT2A，NKAT2B，GL183，NKAT，P58，Receptors， KIR2DL3，Cl-6，Killer Cell Immunoglobulin-Like Receptor Two Domains Long Cytoplasmic Tail 3，Natural Killer Cell Inhibitory Receptor KIR2DL3，Natural Killer Associated Transcript 2，p58.2 MHC class-I-specific NK receptor，Natural killer-associated transcript 2，NKAT-2，NKAT2，p58 natural killer cell receptor clone CL-6，Killer inhibitory receptor cl 2-3，CD158b2，Killer cell immunoglobulin-like receptor 2DL3，KIR2DL3，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 3，CD158 Antigen-Like Family Member B2，P58 NK Receptor CL-6，KIR-023GB，KIRCL23，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Short Cytoplasmic Tail， 5，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 3
Highest Development Stage	Phase 2 Clinical

English Name	Killer cell immunoglobulin-like receptor 2DL3
Target Synonym	P58.2 MHC Class-I Specific NK Receptor，MHC Class I NK Cell Receptor，CD158b2 Antigen，KIR-K7b，KIR-K7c，KIR2DS5，CD158b，KIR2DL，NKAT2A，NKAT2B，GL183，NKAT，P58，Receptors， KIR2DL3，Cl-6，Killer Cell Immunoglobulin-Like Receptor Two Domains Long Cytoplasmic Tail 3，Natural Killer Cell Inhibitory Receptor KIR2DL3，Natural Killer Associated Transcript 2，p58.2 MHC class-I-specific NK receptor，Natural killer-associated transcript 2，NKAT-2，NKAT2，p58 natural killer cell receptor clone CL-6，Killer inhibitory receptor cl 2-3，CD158b2，Killer cell immunoglobulin-like receptor 2DL3，KIR2DL3，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 3，CD158 Antigen-Like Family Member B2，P58 NK Receptor CL-6，KIR-023GB，KIRCL23，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Short Cytoplasmic Tail， 5，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 3
Approved Drugs	0
Drugs in Clinical Trials	1
Highest Development Stage	Phase 2 Clinical

KIR2DL3 Product List

Product Category
Protein (1)
Product Status
Launched (1)
Species
Human (1)
Tag
Fc Tag (1)
Conjugate
Unconjugated (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature	Order Now
KI3-H5258	Human	HEK293	Human KIR2DL3 / CD158b2 / NKAT-2 Protein, Fc Tag (MALS verified)				Add to Cart

Total: 1

KIR2DL3 Background

Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) is also known as CD158 antigen-like family member B2, KIR-023GB, Killer inhibitory receptor cl 2-3, MHC class I NK cell receptor, NKAT2a, NKAT2b, Natural killer-associated transcript 2, p58 natural killer cell receptor clone CL-6, p58.2 MHC class-I-specific NK receptor, CD158b2 and KIR2DL3, which is a single-pass type I membrane protein and belongs to the immunoglobulin superfamily.KIR2DL3 is a receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). KIR2DL3 can inhibit the activity of NK cells thus preventing cell lysis.

KIR2DL3 Synonyms

CD158b2

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Lirilumab	IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015	Phase 2 Clinical	Novo Nordisk A/S	Bone Marrow Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Smoldering Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms	Details